-
November 3, 2022 Compass Pathways Phase 2 Psilocybin Results far from SpectacularPsilocybin showed rapid antidepressant effects for most patients, but only 1 in 5 participants showed...
-
October 21, 2022 Patent Controversies in PsychedelicsWhat investors need to know about the intellectual property behind medicine’s next big growth area
-
October 13, 2022 Math Over Myth: These Psychedelic Stocks Made Confirmed Bottoms in Q3Math over Myth is your weekly update on psychedelic stocks and ETFs, including ATAI, COMPASS,...
-
September 30, 2022 Math Over Myth: September Psychedelic Stock News RoundupTrack the monthly performance of the psychedelic stock sector with our Math over Myth Stock...
-
September 9, 2022 Math Over Myth: Spotlight on Psychedelic Stocks ATAI & COMPASSIf you want to invest in psychedelic stocks, ignore the hype and look at the...
-
August 10, 2022 Compass Pathways Sued for Stealing Trade SecretsCompass Pathways faces a legal challenge from Terran Biosciences over the potential theft of intellectual...
-
July 11, 2022 The Battle for Psychedelic PatentsPsychedelic companies rely on novel patents to boost their value, but many players in the...
-
June 24, 2022 This Week in Psychedelic Stocks: Compass Pathways Wins Patent Battle, MindMed Patents Candy Flipping, and More!This week in psychedelic stock news, there are big patent developments for Compass, MindMed and...
-
June 24, 2022 Compass Pathways Psilocybin Patent UpheldCompass Pathways scores a major victory in their bid to patent Comp 360, a proprietary...
